First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER plus breast cancer with KAT6A dysregulation.

Shikhar Sharma, Thomas A. Paul, Sean Uryu et al.|Cancer Research|2021

Cited by 1